← FDA DRUG APPROVALS

FDA NDA · NDA022254

VIMPAT

lacosamide

Sponsor: UCB INC

APPLICATION
NDA022254
TYPE
NDA
ORIGINAL APPROVAL
2008-10-28
LATEST ACTION
2023-10-16
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

VIMPAT · ReferencePrescription
LACOSAMIDE 200MG/20ML (10MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2023-10-16Labeling · Supplement 47 · standardLetterAP
2023-04-28Efficacy · Supplement 40 · standardLetterAP
2022-09-30Labeling · Supplement 45 · standardLetterAP
2022-05-19Labeling · Supplement 44 · standardLetterAP
2021-10-14Efficacy · Supplement 39 · standardLabelAP
2021-09-15Labeling · Supplement 41 · standardLetterAP
2020-11-16Efficacy · Supplement 38 · standardLabelAP
2020-11-16Efficacy · Supplement 36 · standardLabelAP
2019-06-11Labeling · Supplement 35 · standardLabelAP
2019-01-09Efficacy · Supplement 32 · standardLabelAP
2018-11-11Labeling · Supplement 33 · standardLabelAP
2017-11-03Efficacy · Supplement 30 · standardLabelAP
2017-03-24Labeling · Supplement 29 · standardLabelAP
2016-11-02Manufacturing (CMC) · Supplement 27 · standardAP
2016-07-18Manufacturing (CMC) · Supplement 16 · standardAP
2016-06-10Manufacturing (CMC) · Supplement 26 · standardAP
2015-07-09Labeling · Supplement 22 · standardLabelAP
2014-08-29Efficacy · Supplement 20 · standardLabelAP
2014-08-29Efficacy · Supplement 19 · standardLabelAP
2014-08-12Labeling · Supplement 21 · standardLetterAP
2014-01-16Labeling · Supplement 15 · unknownLabelAP
2013-10-02Manufacturing (CMC) · Supplement 17 · standardAP
2013-09-25Labeling · Supplement 8 · standardLabelAP
2013-09-25Labeling · Supplement 9 · unknownLabelAP
2013-04-17Labeling · Supplement 18 · standardLetterAP
2013-02-08Labeling · Supplement 5 · unknownLetterAP
2013-02-05Labeling · Supplement 14 · standardLabelAP
2011-08-10REMS · Supplement 13LetterAP
2010-04-20Labeling · Supplement 3 · unknownLabelAP
2009-11-18Labeling · Supplement 1 · standardLabelAP
2008-10-28Type 3 - New Dosage Form · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →